ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS
Shots:
- Immunogen to receive $65M as total deal value and OMERS to get royalties on sales of Kadcyla
- In 2015- Immunogen & IRH collaborated for Kadcyla’s royalty for $200M- where IRH received 100% royalties on sales and will own rights till the amount reaches to $235M or $260M. Immunogen to hold 85% of royalties while 15% owned by Genentech (acc. to the 2000 deal of Immunogen & Genetech) on reaching the threshold amount
- Kadcyla (ado-trastuzumab emtansine) is an ADC developed for delivering CT directly to HER2-positive cancer cells and is approved in 104 countries including the US and EU for HER2-positive metastatic breast cancer
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
